title: Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
abstract: Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.
authors.affiliation: Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA. pfsmith@buffalo.edu
authors.forename: Patrick F
authors.initials: PF
authors.lastname: Smith
authors.forename: Gregory K
authors.initials: GK
authors.lastname: Robbins
authors.forename: Robert W
authors.initials: RW
authors.lastname: Shafer
authors.forename: Hulin
authors.initials: H
authors.lastname: Wu
authors.forename: Song
authors.initials: S
authors.lastname: Yu
authors.forename: Martin S
authors.initials: MS
authors.lastname: Hirsch
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Merigan
authors.forename: Jeong-Gun
authors.initials: JG
authors.lastname: Park
authors.forename: Alan
authors.initials: A
authors.lastname: Forrest
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Fischl
authors.forename: Gene D
authors.initials: GD
authors.lastname: Morse
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D048588:Benzoxazines; D003521:Cyclopropanes; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019888:Nelfinavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010078:Oxazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016896:Treatment Outcome
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir; C098320:efavirenz